Vimarsana
Biggest News Aggregation in the World

Mapi Research Trust News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mapi Research Trust. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mapi Research Trust Today - Breaking & Trending Today

ICON Public Limited Company (NASDAQ:ICLR) Q2 2023 Earnings Call Transcript - Vimarsana News

ICON Public Limited Company (NASDAQ:ICLR) Q2 2023 Earnings Call Transcript

Operator: Hello, and welcome to the ICON plc Q2 2023 Results Conference Call. At this time, all participants are in a listen only mode.

ICON Releases Latest Version of its Digital Platform, Providing Integrated Patient Services and Harmonised Data in One Platform - Vimarsana News

ICON Releases Latest Version of its Digital Platform, Providing Integrated Patient Services and Harmonised Data in One Platform

Latest features support greater patient centricity and speed in study start-up

Benralizumab reduces eosinophils but does not improve eosinophilic gastritis - Vimarsana News

Benralizumab reduces eosinophils but does not improve eosinophilic gastritis

Treatment with benralizumab induced histological remission, defined as an absence of tissue eosinophilia, among patients with eosinophilic gastritis, according to a study published in The Lancet Gastroenterology & Hepatology.But the persistence of signs, symptoms and biomarkers of the disease during treatment suggested a pathogenic mechanism independent of eosinophil levels in many patients,

Source: healio.com
Atopic, allergic comorbidities prevalent among patients with eosinophilic esophagitis - Vimarsana News

Atopic, allergic comorbidities prevalent among patients with eosinophilic esophagitis

SAN ANTONIO — A high proportion of patients with eosinophilic esophagitis also had simultaneous atopic or allergic comorbid conditions, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.Eosinophilic esophagitis (EoE) is a chronic, progressive type II inflammatory disease, Marc E. Rothenberg, MD, PhD, director of the Cincinnati Center for

Source: healio.com
eCOA Solution Market to grow at a CAGR of 14.3% from 2022 to 2027, Cloud-based eCOA solutions to be the top segment for the market growth - Vimarsana News

eCOA Solution Market to grow at a CAGR of 14.3% from 2022 to 2027, Cloud-based eCOA solutions to be the top segment for the market growth

/PRNewswire/ -- The global eCOA solution market size is estimated to grow by USD 1,285.69 million from 2022 to 2027, according to Technavio. The market is...